EPIZYME INC's ticker is EPZM and the CUSIP is 29428V104. A total of 94 filers reported holding EPIZYME INC in Q4 2016. The put-call ratio across all filers is 3.03 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $1,118,000 | -23.6% | 82,496 | 0.0% | 0.01% | -26.7% |
| Q1 2018 | $1,464,000 | +32.8% | 82,496 | -6.0% | 0.02% | +50.0% |
| Q4 2017 | $1,102,000 | -37.6% | 87,802 | -5.3% | 0.01% | -28.6% |
| Q3 2017 | $1,765,000 | +23.7% | 92,668 | -2.0% | 0.01% | +16.7% |
| Q2 2017 | $1,427,000 | -12.0% | 94,526 | 0.0% | 0.01% | -14.3% |
| Q1 2017 | $1,621,000 | +41.7% | 94,526 | 0.0% | 0.01% | +55.6% |
| Q4 2016 | $1,144,000 | +23.0% | 94,526 | 0.0% | 0.01% | +28.6% |
| Q3 2016 | $930,000 | -3.9% | 94,526 | 0.0% | 0.01% | -12.5% |
| Q2 2016 | $968,000 | -15.5% | 94,526 | 0.0% | 0.01% | -27.3% |
| Q1 2016 | $1,146,000 | -24.3% | 94,526 | 0.0% | 0.01% | -26.7% |
| Q4 2015 | $1,514,000 | +24.5% | 94,526 | 0.0% | 0.02% | +15.4% |
| Q3 2015 | $1,216,000 | -46.4% | 94,526 | 0.0% | 0.01% | -53.6% |
| Q2 2015 | $2,269,000 | +27.8% | 94,526 | 0.0% | 0.03% | +40.0% |
| Q1 2015 | $1,776,000 | -0.4% | 94,526 | 0.0% | 0.02% | -4.8% |
| Q4 2014 | $1,784,000 | – | 94,526 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 31,833,334 | $47,750,000 | 19.42% |
| MPM BioImpact LLC | 3,425,202 | $3,939,000 | 1.06% |
| Palo Alto Investors LP | 6,774,541 | $7,791,000 | 0.60% |
| Foresite Capital Management I, LLC | 143,759 | $165,000 | 0.29% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 6,603,870 | $7,594,000 | 0.23% |
| Rock Springs Capital Management LP | 7,267,696 | $8,358,000 | 0.21% |
| BP PLC | 24,687 | $28,000 | 0.16% |
| NewGen Asset Management Ltd | 250,000 | $288,000 | 0.13% |
| GSA CAPITAL PARTNERS LLP | 467,836 | $538,000 | 0.07% |
| Frazier Life Sciences Management, L.P. | 739,369 | $850,000 | 0.07% |